May 15, 2025

NMI expertise for new VDI guideline on bioprinting – now available

NMI expertise for new VDI guideline on bioprinting – now available

VDI Guideline 5708 “Bioprinting, methods and definitions”: What sounds technical and sober at first glance is an important step forward in the future field of 3D bioprinting. The guideline was developed under the leadership of Dr. Hanna Hartmann from the NMI Natural and Medical Sciences Institute in Reutlingen as chairwoman and Prof. Dr. Jürgen Groll from the University Hospital of Würzburg as deputy chairman. After around one and a half years of intensive committee work in the transdisciplinary committee, it was adopted as a white paper in April 2024. For the first time, it creates a binding, practical basis for reproducible and quality-assured bioprinting procedures.

Why a guideline? Uniformity, quality, comprehensibility

3D bioprinting is developing dynamically, but a lack of standards has so far made it difficult to compare results, control the quality of bioinks and reproducibly produce structures that can be used in regenerative medicine, to provide test systems for the pharmaceutical industry and for basic cell biology studies. The VDI guideline now closes this gap: It defines key terms, describes methodological principles, recommends minimum requirements for materials, processes and reproducibility and thus supports both research and industrial product development. It is explicitly aimed at all players along the value chain – from research institutions and manufacturers to users and testing laboratories.

Standardized terminology in a transdisciplinary field

With the new publication, the guideline provides manufacturers, researchers and users with a common language for the definition and application of 3D bioprinting technologies. “The transdisciplinary set-up of the guideline committee was a key concern for us,” says Dr. Hanna Hartmann, Head of Biomedicine and Materials Science at the NMI. “It is a decisive step towards harmonizing research and development.” The technical rule has been available via DIN-Media since May 1st: https://www.dinmedia.de/de/technische-regel/vdi-5708-blatt-1/384316908.

Interdisciplinary committee with a clear practical orientation

Under the chairmanship of Dr. Hanna Hartmann and Prof. Dr. Jürgen Groll, an interdisciplinary committee with representatives from research, industry, application and certification worked on the new guideline. In ten meetings, key terms were defined, requirements for materials, processes and quality assurance were formulated and the results were prepared in a practical manner. “VDI 5708 is an important step towards comprehensible and comparable standards,” explains Prof. Jürgen Groll. “These are essential for the development of future products – whether in regenerative medicine, drug testing or in-vitro diagnostics.”

SOP_BioPrint as a basis – funded by the BMBF

The technical basis for the guideline comes from the SOP_BioPrint project (FKZ: 13XP5071C) funded by the Federal Ministry of Education and Research (BMBF). The aim was to develop standardized processes for bioprinting – which have now been incorporated into the guideline.

Further information on the SOP_BioPrint project can be found on the NMI project page​​​​​​​. The BMBF brochure also provides an overview of current developments in bioprinting: Bioprinting – Potenziale für medizinische Forschung und Anwendung.  

Our latest News

discover more
PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

World Novelty: Artificial HPL Solution First Artificial Human Platelet Lysate BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech DewCell Biotherapeutics, PL BioScience […]

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

More Information in German below. EditCo Bio und Promega schließen Partnerschaft, um eine neue Ära biologisch relevanter zellbasierter Forschung einzuläuten Redwood City, CA, USA. (12. Mai 2025) EditCo Bio, Inc. hat eine strategische Lizenzvereinbarung mit der Promega Corporation bekannt gegeben, die EditCo den Zugang zu den Technologien HiBiT, HaloTag® und NanoLuc® von Promega ermöglicht. Diese fortschrittlichen […]

Affimed Announces Filing for the Opening of Insolvency Proceedings

Affimed Announces Filing for the Opening of Insolvency Proceedings

MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the “Company”) […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp